Article Text
Therapeutics/Prevention
Randomised controlled trial
Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome
Statistics from Altmetric.com
Commentary on: OpenUrlCrossRefPubMed
Context
Use of statin therapy to treat dyslipidemia in patients with established coronary artery disease is the standard of care worldwide. Given the negative results of a number of trials that tested the use of adjuvant lipid-lowering therapies against a statin background, there has been great scepticism about whether or not non-statin drugs provide incremental benefit.1–3 Ezetimibe inhibits the absorption of both dietary and biliary cholesterol by inhibiting Niemann Pick C1 Like-1 protein.4 Ezetimibe has been the target of much criticism. Based on the ENHANCE trial,5 it appeared to lack efficacy …